Spectrum of immune checkpoint inhibitors-induced endocrinopathies in cancer patients: a scoping review of case reports

BACKGROUND: Since 2011 six immune checkpoint inhibitors (ICI) have been approved to treat patients with many advanced solid tumor and hematological malignancies to improve their prognosis. Case reports of their endocrine immune-related adverse events [irAEs]) are increasingly published as more real-...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Meng H., Iyengar, Ravi, Mizokami-Stout, Kara, Yentz, Sarah, MacEachern, Mark P., Shen, Li Yan, Redman, Bruce, Gianchandani, Roma
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343255/
https://www.ncbi.nlm.nih.gov/pubmed/30693099
http://dx.doi.org/10.1186/s40842-018-0073-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343255/
https://www.ncbi.nlm.nih.gov/pubmed/30693099
http://dx.doi.org/10.1186/s40842-018-0073-4

Ejemplares similares